Oxford, United Kingdom

Scancell is a clinical-stage immuno-oncology specialist that is developing two innovative and flexible therapeutic vaccine platforms. ImmunoBody and Moditope induce high avidity cytotoxic CD8 and CD4 responses, respectively, with the potential to treat various cancers.

Investment Perspective

Scancell’s outlook has been transformed by the recent investment by Redmile of a further £12.1m in equity and £17.9m in Convertible Loan Notes (CLN). These funds, together with an over-subscribed £3m Open Offer, boost Scancell’s cash to c £48m. After a sustained period of being under-resourced, attention now turns to execution and delivery. The additional funds will be used to progress and broaden the ImmunoBody and Moditope portfolios and further develop the Avidimab platform. The onus will inevitably shift to timely progress across a broader front, including clinical data for SCIB1, Modi-1, and COVIDITY and, in time, material commercial partnerships for Avidimab. We update our valuation to £144m (17.7p per share).

Market information

SymbolPrimary exchanges


Redmile funding releases the brakes
Update | 17 Nov 2020
Redmile endorses technologies with a further £30m
Lighthouse | 12 Oct 2020
UKRI awards funding for COVID-19 trial
Lighthouse | 27 Aug 2020

Recent News

Appointment of CMO and Medical Director
17 Nov 2020
Result of adjourned General Meeting
05 Nov 2020
Conversion of CLNs and total voting rights
02 Nov 2020
Result of open offer and adjournment of General Meeting
29 Oct 2020